Glutamatergic Neurotransmission in the Prefrontal Cortex Mediates the Suppressive Effect of Intra-prelimbic Cortical Infusion of BDNF on Cocaine-seeking
Overview
Psychiatry
Affiliations
Cocaine self-administration induces dysfunctional neuroadaptations in the prefrontal cortex that underlie relapse to cocaine-seeking. Cocaine self-administration disturbs glutamatergic transmission in the nucleus accumbens that is prevented by infusion of brain-derived neurotrophic factor (BDNF) into the prelimbic area of the prefrontal cortex. Intra-prelimbic infusion of BDNF decreases cocaine-seeking in a TrkB-ERK MAP kinase-dependent manner. Neuronal activity triggers an interaction between TrkB receptors and NMDA receptors, leading to ERK activation. In the present study, infusion of the GluN2A-containing NMDA receptor antagonist, TCN-201, or the GluN2B-containing NMDA receptor antagonist, Ro-25-6981, into the prelimbic cortex of rats blocked the suppressive effect of BDNF on cocaine-seeking. During early withdrawal from cocaine self-administration, tyrosine phosphorylation of ERK, GluN2A, and GluN2B in the prelimbic cortex was reduced and this reduction of phospho-proteins was prevented by intra-prelimbic BDNF infusion. TCN-201 infusion into the prelimbic cortex inhibited the BDNF-mediated increase in pERK and pGluN2A whereas Ro-25-6981 infusion into the prelimbic cortex blocked BDNF-induced elevation of pERK and pGluN2B, indicating that both GluN2A- and GluN2B-containing NMDA receptors underlie BDNF-induced ERK activation. These data demonstrate that BDNF-mediated activation of GluN2A- and GluN2B-containing NMDA receptors underlies ERK activation in the prelimbic cortex during early withdrawal, preventing subsequent relapse to cocaine-seeking.
Kim S, Sohn S, Choe E Behav Brain Funct. 2024; 20(1):27.
PMID: 39402674 PMC: 11479554. DOI: 10.1186/s12993-024-00253-y.
Driskill C, Childs J, Phensy A, Rodriguez S, OBrien J, Lindquist K J Neurosci. 2024; 44(23).
PMID: 38719446 PMC: 11154660. DOI: 10.1523/JNEUROSCI.0107-24.2024.
Driskill C, Childs J, Phensy A, Rodriguez S, OBrien J, Lindquist K bioRxiv. 2024; .
PMID: 38328140 PMC: 10849650. DOI: 10.1101/2024.01.25.577293.
Nachtigall E, de C Myskiw J, Izquierdo I, Furini C Psychopharmacology (Berl). 2023; 241(1):61-73.
PMID: 37700085 DOI: 10.1007/s00213-023-06463-y.
BDNF as a therapeutic candidate for cocaine use disorders.
McGinty J Addict Neurosci. 2023; 2.
PMID: 37206683 PMC: 10195100. DOI: 10.1016/j.addicn.2022.100006.